Phase 4 N=66 An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)
Diarrhea · Gastroenteritis
Primary: G1 Serum-neutralizing Antibody — 188; 184.5 titers
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=41 Social Exergaming for Healthy Weight in Adolescent Girls
Obesity and Physical Inactivity in Adolescents
Primary: Change in Body Fat — 1.0; 1.6 kg
Phase 2 N=40 A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) — 18.92 percentage of…
Phase 2 N=33 Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth
Posttraumatic Stress Disorders · PTSD
Primary: Child PTSD Symptom Scale (CPSS) — 15.1; 8.9 units on a scale
N/A N=2,001 Presbyopia Screening by Community Health Worker in Bangladesh
Presbyopia
Primary: Screening Accuracy — 76.9; 75.7; 58.1; 78.3 percentage of cases
Phase 2 N=35 A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
Skin and Connective Tissue Diseases
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling, Infiltration) Absolute Change in Total Clinical Score (TCS) of Clinical Signs…
Phase 1 N=16 A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
Liver Diseases · Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib (LY3009104) — 35.3; 38.2 nanograms per milliliter (ng/mL)
N/A N=45 Obesity, Sleep Apnea, and Insulin Resistance
Insulin Sensitivity · Obstructive Sleep Apnea
Primary: Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo — 35.8; 34.4 AHI events/hour
Phase 4 N=269 BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period — -1.75; -0.73 Score…
Phase 1 N=40 A Study of Baricitinib and Simvastatin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Simvastatin and Simvastatin Acid — 6.85; 4.65; 1.93; 1.60 nanograms per milliliter (ng/mL)
Phase 2 N=82 Patients With Intermittent Claudication Injected With ALDH Bright Cells
Peripheral Artery Disease · Intermittent Claudication
Primary: Peak Walking Time (PWT) — 2.2; 1.2 minutes — p=0.238
Phase 1 N=20 A Study of Baricitinib and Birth Control Pills in Healthy Females
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol — 63.8; 59.7 picograms/milliliter (pg/mL)
Phase 1 N=6 Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
Healthy Volunteers
Primary: Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces — 75.2; 19.9 percentage of total radioactivity
Phase 1 N=18 A Study of Baricitinib and Probenecid in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib — 36.2; 37.3 nanograms/milliliter (ng/mL)
Phase 1 N=28 A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin — 18.7; 16.8 nanograms*hour/milliliter (ng*h/mL)